The clinical utility of lurasidone in schizophrenia: patient considerations

Philip D Harvey1Department of Psychiatry and Behavioral Sciences, University of Miami, Miller School of Medicine, Miami, FL, USA; 2Bruce W Carter VA Medical Center, Miami, FL, USAAbstract: Lurasidone is a novel antipsychotic agent approved for the treatment of schizophrenia in a number of countries...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Harvey PD
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/3158b22e541a469a8d04c2de086c5b6a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3158b22e541a469a8d04c2de086c5b6a
record_format	dspace
spelling	oai:doaj.org-article:3158b22e541a469a8d04c2de086c5b6a2021-12-02T06:52:54ZThe clinical utility of lurasidone in schizophrenia: patient considerations1178-2021https://doaj.org/article/3158b22e541a469a8d04c2de086c5b6a2015-04-01T00:00:00Zhttp://www.dovepress.com/the-clinical-utility-of-lurasidone-in-schizophrenia-patient-considerat-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Philip D Harvey1Department of Psychiatry and Behavioral Sciences, University of Miami, Miller School of Medicine, Miami, FL, USA; 2Bruce W Carter VA Medical Center, Miami, FL, USAAbstract: Lurasidone is a novel antipsychotic agent approved for the treatment of schizophrenia in a number of countries including the United Kingdom, other European countries, the United States, and Canada. In addition to full antagonist activity at the dopamine D2 (Ki, 1 nM) and serotonin 5-HT2A (Ki, 0.5 nM) receptors, the pharmacodynamic profile of lurasidone is notable for its high affinity for serotonin 5-HT7 receptors (0.5 nM) and its partial agonist activity at 5-HT1A receptors (Ki, 6.4 nM). Long-term treatment of schizophrenia with lurasidone has been shown to reduce the risk of relapse in patients with schizophrenia. Lurasidone appears to be associated with minimal effects on body weight, and low risk for clinically meaningful alterations in glucose, lipids, or electrocardiography parameters. Evidence from two randomized trials also suggests improvement in functional capacity and cognitive functioning in people with schizophrenia. A significant evidence base supports the use of lurasidone as a promising agent for the treatment of schizophrenia. Keywords: long-term treatment, antagonist, pharmacodynamic profileHarvey PDDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2015, Iss default, Pp 1103-1109 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Harvey PD The clinical utility of lurasidone in schizophrenia: patient considerations
description	Philip D Harvey1Department of Psychiatry and Behavioral Sciences, University of Miami, Miller School of Medicine, Miami, FL, USA; 2Bruce W Carter VA Medical Center, Miami, FL, USAAbstract: Lurasidone is a novel antipsychotic agent approved for the treatment of schizophrenia in a number of countries including the United Kingdom, other European countries, the United States, and Canada. In addition to full antagonist activity at the dopamine D2 (Ki, 1 nM) and serotonin 5-HT2A (Ki, 0.5 nM) receptors, the pharmacodynamic profile of lurasidone is notable for its high affinity for serotonin 5-HT7 receptors (0.5 nM) and its partial agonist activity at 5-HT1A receptors (Ki, 6.4 nM). Long-term treatment of schizophrenia with lurasidone has been shown to reduce the risk of relapse in patients with schizophrenia. Lurasidone appears to be associated with minimal effects on body weight, and low risk for clinically meaningful alterations in glucose, lipids, or electrocardiography parameters. Evidence from two randomized trials also suggests improvement in functional capacity and cognitive functioning in people with schizophrenia. A significant evidence base supports the use of lurasidone as a promising agent for the treatment of schizophrenia. Keywords: long-term treatment, antagonist, pharmacodynamic profile
format	article
author	Harvey PD
author_facet	Harvey PD
author_sort	Harvey PD
title	The clinical utility of lurasidone in schizophrenia: patient considerations
title_short	The clinical utility of lurasidone in schizophrenia: patient considerations
title_full	The clinical utility of lurasidone in schizophrenia: patient considerations
title_fullStr	The clinical utility of lurasidone in schizophrenia: patient considerations
title_full_unstemmed	The clinical utility of lurasidone in schizophrenia: patient considerations
title_sort	clinical utility of lurasidone in schizophrenia: patient considerations
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/3158b22e541a469a8d04c2de086c5b6a
work_keys_str_mv	AT harveypd theclinicalutilityoflurasidoneinschizophreniapatientconsiderations AT harveypd clinicalutilityoflurasidoneinschizophreniapatientconsiderations
_version_	1718399682523168768

The clinical utility of lurasidone in schizophrenia: patient considerations

Ejemplares similares